Home » Stocks » CCXI

ChemoCentryx, Inc. (CCXI)

Stock Price: $46.54 USD -0.61 (-1.29%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $46.45 -0.09 (-0.19%) Apr 16, 5:15 PM
Market Cap 3.25B
Revenue (ttm) 64.89M
Net Income (ttm) -55.36M
Shares Out 65.69M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $46.54
Previous Close $47.15
Change ($) -0.61
Change (%) -1.29%
Day's Open 47.74
Day's Range 46.38 - 48.58
Day's Volume 314,747
52-Week Range 44.68 - 70.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the first hal...

1 week ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET....

1 week ago - GlobeNewsWire

ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...

3 weeks ago - Zacks Investment Research

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company's Executive Vice President and Chief Financi...

1 month ago - GlobeNewsWire

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.

1 month ago - Zacks Investment Research

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -34.38% and -51.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associated ...

1 month ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upco...

1 month ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after...

1 month ago - GlobeNewsWire

-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan's effec...

2 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upco...

3 months ago - GlobeNewsWire

ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.

3 months ago - Zacks Investment Research

MOUNTAIN VIEW, Calif. and ST. GALLEN, Switzerland, Dec. 21, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from the ACCOL...

3 months ago - GlobeNewsWire

ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upco...

4 months ago - GlobeNewsWire

ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.

5 months ago - Zacks Investment Research

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -25.00% and -60.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 59.09% year over year to ($0.35), which miss...

5 months ago - Benzinga

-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing Authorizati...

5 months ago - GlobeNewsWire

-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -- MOUNTAIN...

5 months ago - GlobeNewsWire

ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the European Med...

5 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close o...

5 months ago - GlobeNewsWire

-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at ...

5 months ago - GlobeNewsWire

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Final Trades: AT&T, Jumia Technologies, Chemocentryx, General Motors

YouTube video

The “Halftime Report” traders give their top picks to watch for the second half.

Other stocks mentioned: GM, JMIA, T
5 months ago - CNBC Television

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: ADAP, KOD, MCRB, MYOV, NVAX, SRNE
6 months ago - InvestorPlace

The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.

7 months ago - Zacks Investment Research

-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration ...

7 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H...

7 months ago - GlobeNewsWire

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 185.29% and 494.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

-- U.S. New Drug Application (NDA) submitted for avacopan in ANCA-associated vasculitis -- -- Balance sheet bolstered with $325.7 million in net proceeds from June follow-on offering; total cash, cash...

8 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market clos...

8 months ago - GlobeNewsWire

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

MOUNTAIN VIEW, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Admini...

9 months ago - GlobeNewsWire

Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 i...

9 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. ChemoCentry...

10 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at ...

10 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock.  In connection with...

10 months ago - GlobeNewsWire

ChemoCentryx: Avacopan's Attractive Value Proposition

10 months ago - Seeking Alpha

MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a ...

11 months ago - GlobeNewsWire

ChemoCentryx, Inc. (CCXI) CEO Dr.

11 months ago - Seeking Alpha

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -16.67% and -32.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.

11 months ago - Zacks Investment Research

ChemoCentryx (CCXI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

Other stocks mentioned: AXSM, DXCM, EIDX, ENPH
1 year ago - GuruFocus

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

Other stocks mentioned: ARCT, AUPH, KDMN, NVAX, NVRO, TMO
1 year ago - InvestorPlace

ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

About CCXI

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The... [Read more...]

Industry
Biotechnology
IPO Date
Feb 8, 2012
CEO
Thomas Schall
Employees
133
Stock Exchange
NASDAQ
Ticker Symbol
CCXI
Full Company Profile

Financial Performance

In 2020, ChemoCentryx's revenue was $64.89 million, an increase of 79.61% compared to the previous year's $36.13 million. Losses were -$55.36 million, -0.24% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ChemoCentryx stock is "Buy." The 12-month stock price forecast is 88.88, which is an increase of 90.98% from the latest price.

Price Target
$88.88
(90.98% upside)
Analyst Consensus: Buy